In this complimentary podcast hear Dave Dimond, Chief Innovation Officer for Dell EMC Healthcare and Life Sciences as he speaks with James Lowey, Chief Information Officer for The Translational Genomics Research Institute, or TGen, about its Precision Medicine IT transformation journey. Hear how James brings his strategic imaginative and prescient and management to all features of IT by working carefully with the scientific and administrative management of TGen to make sure the best superior applied sciences are in manufacturing on the proper time.
TGen’s a non-profit genomics research institute, and my understanding is that TGen conducts research round genetic discovery to enhance illness outcomes, and does so creating smarter diagnostics and focused therapeutics. With that intro, James, what are you able to inform us concerning the work that TGen’s doing at the moment?
You are right. More than 16 years in the past, TGen was based as a one-of-a-kind genomics research institute. Today, TGen just isn’t solely an integral piece of Arizona’s statewide bioscience initiative, but additionally a world-class middle of innovation. We repeatedly transfer the needle with regard to advancing precision medicine. TGen companions with researchers and docs across the globe to share diagnostic and case data to supply extra personalised therapy.
Our work is targeted totally on most cancers, however we additionally work with neurogenic circumstances comparable to Alzheimer’s, and metabolic illnesses comparable to Diabetes, together with uncommon childhood problems handed down by means of inheritance, and we focus on underserved populations — so-called “orphan” illnesses — uncommon well being circumstances that would not have a excessive sufficient prevalence to justify massive, randomized clinical trials.
In the sunshine of all of at the moment’s technological developments, we nonetheless face appreciable challenges: We have to course of 90 billion information factors for every human genome sequence. All of this information is saved for entry by different collaborators or medical suppliers — now and later. And all of this information must be processed, analyzed, securely communicated and finally used to supply actionable insights.
This continues to supply an impediment to the work of TGen and the sector of precision medicine. But it’s an impediment that must be addressed – significantly as TGen now begins to maneuver from research-driven options to clinical utility. We are in search of methods to make the science relevant within the bigger clinical context, which suggests unprecedented scale.
We urge you to click on on the podcast hyperlink for extra in depth dialog on how TGen continues to drive the transition from scientific research into clinical utility.